Handbook of Targeted Cancer Therapy and Immunotherapy

 

Description:

Designed for quick, everyday reference, Handbook of Targeted Cancer Therapy and Immunotherapy, 3rd Edition, includes clinical trial results of more than 250 state-of-the-art targeted therapy and immunotherapy agents, providing a practical, intuitive, colorful overview of this rapidly advancing field. Comprehensive yet concise, this easy-access resource by Drs. Daniel D. Karp, Gerald S. Falchook, and JoAnn D. Lim, helps you navigate through the newest research reports and apply the most recent discoveries as they pertain to specific tumor types, actionable molecular targets, and clinical performance of investigational targeted agents and combinations of agents.  This handbook presents information distilled by dozens of translational research clinicians and other healthcare experts with hundreds of years of cumulative experience in the revolutionary area of genomically based precision oncology.

 

Table of Contents:

 

SECTION 1 Targets by Organ Site

Color Key

Abbreviations

Adrenocortical Carcinoma (ACC)—Mouhammed A. Habra, Aung Naing

Agnostic to Tumor Site—Gerald S. Falchook

Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct, Cholangiocarcinoma)—Goldy C. George, David S. Hong, Milind Javle, Kathrina Marcelo-Lewis, Ahmed O. Kaseb

Bladder Carcinoma (Urothelial Cancer)—Arlene O. Siefker-Radtke

Brain Tumors—Michael Pearlman, Vivek Subbiah Glioblastoma/Malignant Gliomas

Other NF-Related Tumors

Medulloblastoma

Meningiomas

Breast Cancer—Senthil Damodaran, Debu Tripathy ER/PR+

HER2+

Triple-Negative/Basal

Cervical Cancer—Siqing Fu, Laura L. Holman, Shannon N. Westin

Colorectal Cancer—David S. Hong, E. Scott Kopetz, Allan A. L. Pereira

Esophageal Cancer (Squamous Cell)—Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy

Gastric/Gastroesophageal Junction Adenocarcinoma—Ahmed Abdelhakeem, Goldy C. George, David S. Hong, Mariela B. Murphy

Head and Neck Cancer—Renata Ferrarotto, Sangeeta Goswami, Kathrina Marcelo-Lewis, Sarina A. Piha-Paul, Erminia Massarelli Salivary Gland

Squamous Cell

Nasopharynx

Kidney (Renal Cell) Cancer—Vivek Subbiah, Nizar M. Tannir

Leukemia—Prajwal C. Boddu, Tapan M. Kadia, Radhika Kainthla, Naveen Pemmaraju Acute Myeloid Leukemia (AML)

Acute Lymphoblastic Leukemia (ALL)

Chronic Myeloid Leukemia (CML)

Chronic Lymphocytic Leukemia (CLL)

Myeloproliferative Neoplasm (MPN)

Liver Cancer (Hepatocellular)—Ahmed O. Kaseb, Xiaochun Liu, Shiraj Sen

Lung Cancer—Niamh Coleman, Daniel D. Karp, Kathrina Marcelo-Lewis, Ralph G. Zinner NSCLC

SCLC

Lymphoma—Maliha Khan, Xiaochun Liu, Raphael Steiner, Jason R. Westin

Multiple Myeloma—Manojkumar Bupathi, Gregory Kaufman, Robert Orlowski

Ovarian Cancer—Siqing Fu, Laura L. Holman, Shannon N. Westin

Pancreatic Cancer (Ductal Carcinoma)—Goldy C. George, Milind Javle, Kathrina Marcelo-Lewis, Shubham Pant

Prostate Cancer (Adenocarcinoma)—Patrick Pilie

Sarcoma—Anthony Conley, David S. Hong, Jason Roszik, Vivek Subbiah Gastrointestinal Stromal Tumors, GIST

Sarcoma

Skin Cancer—Gerald S. Falchook, Meredith A. McKean, Michael K. K. Wong, Scott E. Woodman Melanoma

Basal Cell

Squamous Cell

Merkel Cell

Small Bowel Cancer—Gerald S. Falchook

Testicular Cancer (Germ Cell Carcinoma)—Lance C. Pagliaro, Vivek Subbiah

Thymus Carcinoma (Thymic and Thymoma)—Gerald S. Falchook, Ralph G. Zinner

Thyroid Cancer—Manojkumar Bupathi, Maria E. Cabanillas, Gerald S. Falchook Papillary and Follicular Carcinoma

Papillary, Follicular, and Hurthle Cell Carcinoma

Medullary Carcinoma

Anaplastic Carcinoma

Uterine (Endometrial) Cancer—Siqing Fu, Laura L. Holman, Shannon N. Westin

SECTION 2 Carcinogenesis from the Perspective of Targeted Therapy and Immunotherapy

SECTION 3 Molecular Targets and Pathways

An Introduction to the Organization of Cancer Cell Signaling

Signal Transduction Roadmap

VEGF and VEGFR

FGF and FGFR

PDGF and PDGFR

Angiopoietin and TIE Receptors

IGFR and Insulin Receptors

Targeting IGFR and Insulin Receptors

TGFβ/SMAD

EGFR

EGFR Signaling

HER2 (Also Known as ERBB2)

MET (Also Known as HGF Receptor)

RET Receptor

ALK Receptor

KIT Receptor

ROS Receptor

Receptor Tyrosine Kinases (Activation Cascade)

Cell Signaling Pathways Rapamycin and Its Mammalian Target (mTOR)

PI3K-AKT-mTOR Pathway

PI3K, AKT, PTEN, TSC in Cancer

mTORC1,2

NF-Kappa B—Master Immune Regulator

NF-κB Pathway

G-Protein-Coupled Receptors

Mitogen-Activated Protein Kinase (MAPK)

RAS/MAPK Pathway

Targeting BRAF/MEK

Rous Sarcoma Virus Oncogene (SRC)

SRC Pathway

β-Catenin–Cell Adhesion

Wnt Pathway

Fruit Fly Mutations and Related Genes

Hedgehog Pathway

NOTCH Pathway

B-Cell Lymphoma 2 (BCL-2)/Cysteine Aspartates (CASPASES)

Janus Kinase and Signal Transducer and Transcription

JAK/STAT Pathway

Apoptosis (Greek—“Leaves Falling from a Tree”)

Death Receptors (DRs) and Apoptosis

Nuclear Factors and DNA Repair

TP53: Master Cell Cycle Regulator

Cell Regulation by RB1, CDKs

DNA Damage Response

Aurora Kinase

Overview of Angiogenic Signaling

Angiogenesis: A Hallmark of Cancer

Angiogenesis Regulators

Immunotherapy

Management of Immune-Related Adverse Events (irAEs)

Epigenetics

Targeting Epigenetics

Antibody Drug Conjugates (ADCs) Have Variable “Payloads” and Multiple Microenvironmental Targets

Tropomyosin-Related Kinases

Metabolism: Glycolysis and the TCA Cycle

Targeting Cancer Metabolism

Ewing Sarcoma Gene Fusion

SECTION 4 Targeted and Immunotherapy Agents

Color Key

Abbreviations

Abemaciclib

Abiraterone Acetate

Acalabrutinib

Acalisib

Adavosertib

Ado-Trastuzumab Emtansine

Afatinib Dimaleate

Afuresertib

Alectinib

Alemtuzumab (Campath-1H)

Alisertib

All-Trans Retinoic Acid (ATRA)

Alpelisib

Alrizomadlin

Altiratinib

AMG337

Amivantamab-vmjw

Anastrozole

Andecaliximab (GS-5745)

Anetumab Ravtansine

Anlotinib

Apalutamide

Apatinib

Atezolizumab

Avapritinib

Avelumab

Axicabtagene Ciloleucel

Axitinib

Belagenpumatucel-L

Belantamab Mafodotin

Belinostat

Belizatinib

Bemarituzumab

Bempegaldesleukin

Berzosertib

Bevacizumab

BI 811283

Bicalutamide

Binimetinib

Bintrafusp Alfa

Blinatumomab

BMS-936559

Bortezomib

Bosutinib

Brentuximab Vedotin

Brexucabtagene Autoleucel

Brigatinib

Brivanib Alaninate

Bryostatin 1

Buparlisib

Cabozantinib

Camrelizumab

Capivasertib

Capmatinib

Carfilzomib

Cediranib Maleate

Cemiplimab

Ceritinib

Cetuximab

Cevostamab

Ciltacabtagene Autoleucel

Cixutumumab

Cobimetinib Fumarate

Copanlisib

Crenolanib Besylate

Crizotinib

Dabrafenib

Dacomitinib

Dactolisib

Danvatirsen

Daratumumab

Darolutamide

Darovasertib

Dasatinib

Debio-1347

Demcizumab

Dostarlimab

Double Antiangiogenic Protein

Dovitinib

Durvalumab

Duvelisib

Elotuzumab

Enasidenib Mesylate

Encorafenib

Enfortumab Vedotin

Ensartinib

Entrectinib

Enzalutamide

Enzastaurin

Epratuzumab

Erdafitinib

Erlotinib

Everolimus

Farletuzumab

Ficlatuzumab

Figitumumab

Foretinib

Fostamatinib Disodium

Fulvestrant

Futibatinib

Galunisertib

Ganitumab

Gefitinib

Geldanamycin

Gemtuzumab Ozogamicin

Gilteritinib Fumarate

Glasdegib Maleate

Ibrutinib

Icotinib

Idecabtagene Vicleucel

Idelalisib

Imatinib Mesylate

Imifoplatin397

Iniparib

Inotuzumab Ozogamicin

Ipafricept

Ipatasertib

Ipilimumab

Isatuximab

Ivosidenib

Lanreotide

Lapatinib Ditosylate

Larotrectinib

Lenalidomide

Lenvatinib Mesylate

LGK974

Linifanib

Linsitinib

Loncastuximab Tesirine

Lorlatinib

Lucitanib

Lurbinectedin

Lutetium Lu 177 Dotatate

Margetuximab-cmkb

Matuzumab

Midostaurin

Milademetan

Miransertib

Mirvetuximab Soravtansine

MK-0752

MK-2206

MK-8242

MKC-1

Mocetinostat

Mogamulizumab-kpkc

Momelotinib

nab-Rapamycin

Napabucasin

Naquotinib Mesylate

Navitoclax

Nazartinib

Necitumumab

Neratinib

Nilotinib

Nintedanib

Niraparib

Nirogacestat

Nivolumab

Obatoclax Mesylate

Obinutuzumab

Ofatumumab

Olaparib

Olaratumab

Olmutinib

Onartuzumab

Onatasertib

Osimertinib

Pacritinib

Palbociclib

Panitumumab

Panobinostat

Parsaclisib

Pazopanib Hydrochloride

Pelareorep

Pembrolizumab

Pemetrexed

Pemigatinib

Peposertib

Perifosine

Pertuzumab

Pexidartinib

Pilaralisib

Pimasertib

Pomalidomide

Ponatinib Hydrochloride

Poziotinib

Pralatrexate

Pralsetinib

Prexasertib

Pyrotinib

Quizartinib

Ramucirumab

Razuprotafib

RC48-ADC

Rebastinib

Refametinib

Regorafenib

Ridaforolimus

Rigosertib

Rilotumumab

Ripretinib

Rituximab

Romidepsin

Rovalpituzumab Tesirine

Rucaparib Camsylate

Ruxolitinib Phosphate

Sacituzumab Govitecan

Sapanisertib

Saracatinib

Selinexor

Selitrectinib

Selpercatinib

Selumetinib

Serabelisib

Sintilimab

Sipuleucel-T

Sirolimus

Sitravatinib

Sonidegib

Sonolisib

Sorafenib

Sotatercept

Sotorasib

Spartalizumab

Sunitinib

TAK580

Taladegib

Talazoparib Tosylate

Taletrectinib

Talimogene Laherparepvec

Talquetamab

Tazemetostat Hydrobromide

Teclistamab

Telaglenastat

Telatinib

Temsirolimus

Tepotinib

Thalidomide

Tipifarnib

Tirabrutinib

Tisagenlecleucel

Tisotumab Vedotin-tftv

Tivantinib

Toripalimab

Trabectedin

Trabedersen

Trametinib

Trastuzumab

Trebananib

Tremelimumab

Tucatinib

Ulixertinib

Uprosertib

Urelumab

Vadastuximab Talirine

Valproic Acid

Vandetanib

Vanucizumab

Vatalanib

Veliparib

Vemurafenib

Venetoclax

Vevorisertib

Vismodegib

Vistusertib

Vocimagene Amiretrorepvec

Vopratelimab

Vorinostat

Xentuzumab

Zalutumumab

Zanidatamab

Zanubrutinib

Ziv-Aflibercept

Zotatifin

Index

 

An aparitie	16 Jul 2022
Autor	Daniel D. Karp, Gerald S. Falchook MD, MS, JoAnn D. Lim
Dimensiuni	108 x 181 mm
Editura	LWW
Format	Paperback
ISBN	9781975179243
Limba	Engleza
Nr pag	520
Versiune digitala	DA